Therapeutic potential of the genus Zanthoxylum phytochemicals: A theoretical ADME/Tox analysis
•Zanthoxylum is a genus with over 220 species that are endemic to the tropics and subtropics.•Alkaloids make up 35.2% of the 406 compounds reported in this genus (as of June 2023).•Based on predicted drug-likeness, 81% of Zanthoxylum compounds obey Lipinski's rule of five.•Zanthoxylum compounds...
Gespeichert in:
Veröffentlicht in: | South African journal of botany 2023-11, Vol.162, p.129-141 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 141 |
---|---|
container_issue | |
container_start_page | 129 |
container_title | South African journal of botany |
container_volume | 162 |
creator | Wekesa, Emily N. Kimani, Njogu M. Kituyi, Sarah N. Omosa, Leonidah K. Santos, Cleydson B.R. |
description | •Zanthoxylum is a genus with over 220 species that are endemic to the tropics and subtropics.•Alkaloids make up 35.2% of the 406 compounds reported in this genus (as of June 2023).•Based on predicted drug-likeness, 81% of Zanthoxylum compounds obey Lipinski's rule of five.•Zanthoxylum compounds have comparable physicochemical properties to FDA-approved drugs.
Natural products (NPs) are essential in the search for new drugs to treat a wide range of diseases, including infectious and malignant disorders. However, despite the discovery of many bioactive NPs, they often do not make it to market as drugs due to toxicity and other challenges. The development of NPs into drugs is a long and expensive process, and many promising compounds are abandoned along the way. These molecules require in silico ADMET profiling in order to speed up their development into drugs lower costs, and the high attrition rate. The objective of this work was to produce thorough ADMET profiles of secondary metabolites from several classes that were isolated from Zanthoxylum species. The genus has a long history of therapeutic use, including treating tumours, hypertension, gonorrhea, coughs, bilharzia, chest pains, and toothaches. The study used a dataset of 406 compounds from the genus for theoretical ADMET analysis. The findings revealed that 81% of the compounds met Lipinski's rule of five, indicating good oral bioavailability. The drug-likeness criteria were taken into account, with percentages ranging from 66.2 to 88.1 percent. Additionally, 9.2% of the compounds were predicted to be lead-like, demonstrating their potential as promising drug development candidates. Interestingly, none of the compounds inhibited hERG I, while 33% inhibited hERG II, potentially having cardiac implications. Additionally, 30% of the compounds exhibited AMES toxicity inhibition, while 23.6% were identified as hepatotoxic and 22.2% would cause skin sensitivity. Moreover, 81.8% of the compounds demonstrated high intestinal absorption, making them desirable for oral drugs. In conclusion, these findings highlight the diverse properties of the investigated compounds and their potential for drug development. |
doi_str_mv | 10.1016/j.sajb.2023.09.009 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10569136</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0254629923005422</els_id><sourcerecordid>2878017127</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-775abcd982ce46a1eb84e90024a0be42ec91623271a0b22426ebaad33a6818e03</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EokvhD3BAOXJJOv5IHCMktGpLi1TEZblwwHKc2carJF5sp-r-exK2VHCBkzXyM69m5iHkNYWCAq3OdkU0u6ZgwHgBqgBQT8iKSiZzxRl9SlbASpFXTKkT8iLGHQDlrGbPyQmXtYCylCvyfdNhMHuckrPZ3icckzN95rdZ6jC7xXGK2Tczps7fH_ppyPbdIXnb4eCs6eO7bL1wPmBa6mx98fnybOPvMzOa_hBdfEmebWcOXz28p-Trx8vN-XV-8-Xq0_n6JreiVimXsjSNbVXNLIrKUGxqgQqACQMNCoZW0YpxJulcMyZYhY0xLeemqmmNwE_Jh2PufmoGbO28RjC93gc3mHDQ3jj998_oOn3r7zSFslKUV3PC24eE4H9MGJMeXLTY92ZEP0XNQYCQcr7uf1FWyxqopL9QdkRt8DEG3D6OREEvEvVOLxL1IlGD0rPEuenNn8s8tvy2NgPvjwDOJ71zGHS0DkeLrQtok269-1f-T6jWry8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2878017127</pqid></control><display><type>article</type><title>Therapeutic potential of the genus Zanthoxylum phytochemicals: A theoretical ADME/Tox analysis</title><source>Elsevier ScienceDirect Journals</source><creator>Wekesa, Emily N. ; Kimani, Njogu M. ; Kituyi, Sarah N. ; Omosa, Leonidah K. ; Santos, Cleydson B.R.</creator><creatorcontrib>Wekesa, Emily N. ; Kimani, Njogu M. ; Kituyi, Sarah N. ; Omosa, Leonidah K. ; Santos, Cleydson B.R.</creatorcontrib><description>•Zanthoxylum is a genus with over 220 species that are endemic to the tropics and subtropics.•Alkaloids make up 35.2% of the 406 compounds reported in this genus (as of June 2023).•Based on predicted drug-likeness, 81% of Zanthoxylum compounds obey Lipinski's rule of five.•Zanthoxylum compounds have comparable physicochemical properties to FDA-approved drugs.
Natural products (NPs) are essential in the search for new drugs to treat a wide range of diseases, including infectious and malignant disorders. However, despite the discovery of many bioactive NPs, they often do not make it to market as drugs due to toxicity and other challenges. The development of NPs into drugs is a long and expensive process, and many promising compounds are abandoned along the way. These molecules require in silico ADMET profiling in order to speed up their development into drugs lower costs, and the high attrition rate. The objective of this work was to produce thorough ADMET profiles of secondary metabolites from several classes that were isolated from Zanthoxylum species. The genus has a long history of therapeutic use, including treating tumours, hypertension, gonorrhea, coughs, bilharzia, chest pains, and toothaches. The study used a dataset of 406 compounds from the genus for theoretical ADMET analysis. The findings revealed that 81% of the compounds met Lipinski's rule of five, indicating good oral bioavailability. The drug-likeness criteria were taken into account, with percentages ranging from 66.2 to 88.1 percent. Additionally, 9.2% of the compounds were predicted to be lead-like, demonstrating their potential as promising drug development candidates. Interestingly, none of the compounds inhibited hERG I, while 33% inhibited hERG II, potentially having cardiac implications. Additionally, 30% of the compounds exhibited AMES toxicity inhibition, while 23.6% were identified as hepatotoxic and 22.2% would cause skin sensitivity. Moreover, 81.8% of the compounds demonstrated high intestinal absorption, making them desirable for oral drugs. In conclusion, these findings highlight the diverse properties of the investigated compounds and their potential for drug development.</description><identifier>ISSN: 0254-6299</identifier><identifier>EISSN: 1727-9321</identifier><identifier>DOI: 10.1016/j.sajb.2023.09.009</identifier><identifier>PMID: 37840557</identifier><language>eng</language><publisher>South Africa: Elsevier B.V</publisher><subject>ADMET profiling ; Alkaloids ; bioavailability ; chest ; computer simulation ; data collection ; drug development ; Drug discovery ; Drug-likeness ; genus ; hepatotoxicity ; hypertension ; intestinal absorption ; Lead likeness ; Natural products ; phytochemicals ; Phytochemistry ; Secondary metabolites ; species ; therapeutics ; Zanthoxylum</subject><ispartof>South African journal of botany, 2023-11, Vol.162, p.129-141</ispartof><rights>2023 SAAB</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-775abcd982ce46a1eb84e90024a0be42ec91623271a0b22426ebaad33a6818e03</citedby><cites>FETCH-LOGICAL-c489t-775abcd982ce46a1eb84e90024a0be42ec91623271a0b22426ebaad33a6818e03</cites><orcidid>0000-0002-2074-1653 ; 0000-0003-3890-7794 ; 0000-0002-5171-1940</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0254629923005422$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37840557$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wekesa, Emily N.</creatorcontrib><creatorcontrib>Kimani, Njogu M.</creatorcontrib><creatorcontrib>Kituyi, Sarah N.</creatorcontrib><creatorcontrib>Omosa, Leonidah K.</creatorcontrib><creatorcontrib>Santos, Cleydson B.R.</creatorcontrib><title>Therapeutic potential of the genus Zanthoxylum phytochemicals: A theoretical ADME/Tox analysis</title><title>South African journal of botany</title><addtitle>S Afr J Bot</addtitle><description>•Zanthoxylum is a genus with over 220 species that are endemic to the tropics and subtropics.•Alkaloids make up 35.2% of the 406 compounds reported in this genus (as of June 2023).•Based on predicted drug-likeness, 81% of Zanthoxylum compounds obey Lipinski's rule of five.•Zanthoxylum compounds have comparable physicochemical properties to FDA-approved drugs.
Natural products (NPs) are essential in the search for new drugs to treat a wide range of diseases, including infectious and malignant disorders. However, despite the discovery of many bioactive NPs, they often do not make it to market as drugs due to toxicity and other challenges. The development of NPs into drugs is a long and expensive process, and many promising compounds are abandoned along the way. These molecules require in silico ADMET profiling in order to speed up their development into drugs lower costs, and the high attrition rate. The objective of this work was to produce thorough ADMET profiles of secondary metabolites from several classes that were isolated from Zanthoxylum species. The genus has a long history of therapeutic use, including treating tumours, hypertension, gonorrhea, coughs, bilharzia, chest pains, and toothaches. The study used a dataset of 406 compounds from the genus for theoretical ADMET analysis. The findings revealed that 81% of the compounds met Lipinski's rule of five, indicating good oral bioavailability. The drug-likeness criteria were taken into account, with percentages ranging from 66.2 to 88.1 percent. Additionally, 9.2% of the compounds were predicted to be lead-like, demonstrating their potential as promising drug development candidates. Interestingly, none of the compounds inhibited hERG I, while 33% inhibited hERG II, potentially having cardiac implications. Additionally, 30% of the compounds exhibited AMES toxicity inhibition, while 23.6% were identified as hepatotoxic and 22.2% would cause skin sensitivity. Moreover, 81.8% of the compounds demonstrated high intestinal absorption, making them desirable for oral drugs. In conclusion, these findings highlight the diverse properties of the investigated compounds and their potential for drug development.</description><subject>ADMET profiling</subject><subject>Alkaloids</subject><subject>bioavailability</subject><subject>chest</subject><subject>computer simulation</subject><subject>data collection</subject><subject>drug development</subject><subject>Drug discovery</subject><subject>Drug-likeness</subject><subject>genus</subject><subject>hepatotoxicity</subject><subject>hypertension</subject><subject>intestinal absorption</subject><subject>Lead likeness</subject><subject>Natural products</subject><subject>phytochemicals</subject><subject>Phytochemistry</subject><subject>Secondary metabolites</subject><subject>species</subject><subject>therapeutics</subject><subject>Zanthoxylum</subject><issn>0254-6299</issn><issn>1727-9321</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkU1v1DAQhi0EokvhD3BAOXJJOv5IHCMktGpLi1TEZblwwHKc2carJF5sp-r-exK2VHCBkzXyM69m5iHkNYWCAq3OdkU0u6ZgwHgBqgBQT8iKSiZzxRl9SlbASpFXTKkT8iLGHQDlrGbPyQmXtYCylCvyfdNhMHuckrPZ3icckzN95rdZ6jC7xXGK2Tczps7fH_ppyPbdIXnb4eCs6eO7bL1wPmBa6mx98fnybOPvMzOa_hBdfEmebWcOXz28p-Trx8vN-XV-8-Xq0_n6JreiVimXsjSNbVXNLIrKUGxqgQqACQMNCoZW0YpxJulcMyZYhY0xLeemqmmNwE_Jh2PufmoGbO28RjC93gc3mHDQ3jj998_oOn3r7zSFslKUV3PC24eE4H9MGJMeXLTY92ZEP0XNQYCQcr7uf1FWyxqopL9QdkRt8DEG3D6OREEvEvVOLxL1IlGD0rPEuenNn8s8tvy2NgPvjwDOJ71zGHS0DkeLrQtok269-1f-T6jWry8</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Wekesa, Emily N.</creator><creator>Kimani, Njogu M.</creator><creator>Kituyi, Sarah N.</creator><creator>Omosa, Leonidah K.</creator><creator>Santos, Cleydson B.R.</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2074-1653</orcidid><orcidid>https://orcid.org/0000-0003-3890-7794</orcidid><orcidid>https://orcid.org/0000-0002-5171-1940</orcidid></search><sort><creationdate>20231101</creationdate><title>Therapeutic potential of the genus Zanthoxylum phytochemicals: A theoretical ADME/Tox analysis</title><author>Wekesa, Emily N. ; Kimani, Njogu M. ; Kituyi, Sarah N. ; Omosa, Leonidah K. ; Santos, Cleydson B.R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-775abcd982ce46a1eb84e90024a0be42ec91623271a0b22426ebaad33a6818e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>ADMET profiling</topic><topic>Alkaloids</topic><topic>bioavailability</topic><topic>chest</topic><topic>computer simulation</topic><topic>data collection</topic><topic>drug development</topic><topic>Drug discovery</topic><topic>Drug-likeness</topic><topic>genus</topic><topic>hepatotoxicity</topic><topic>hypertension</topic><topic>intestinal absorption</topic><topic>Lead likeness</topic><topic>Natural products</topic><topic>phytochemicals</topic><topic>Phytochemistry</topic><topic>Secondary metabolites</topic><topic>species</topic><topic>therapeutics</topic><topic>Zanthoxylum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wekesa, Emily N.</creatorcontrib><creatorcontrib>Kimani, Njogu M.</creatorcontrib><creatorcontrib>Kituyi, Sarah N.</creatorcontrib><creatorcontrib>Omosa, Leonidah K.</creatorcontrib><creatorcontrib>Santos, Cleydson B.R.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>South African journal of botany</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wekesa, Emily N.</au><au>Kimani, Njogu M.</au><au>Kituyi, Sarah N.</au><au>Omosa, Leonidah K.</au><au>Santos, Cleydson B.R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic potential of the genus Zanthoxylum phytochemicals: A theoretical ADME/Tox analysis</atitle><jtitle>South African journal of botany</jtitle><addtitle>S Afr J Bot</addtitle><date>2023-11-01</date><risdate>2023</risdate><volume>162</volume><spage>129</spage><epage>141</epage><pages>129-141</pages><issn>0254-6299</issn><eissn>1727-9321</eissn><abstract>•Zanthoxylum is a genus with over 220 species that are endemic to the tropics and subtropics.•Alkaloids make up 35.2% of the 406 compounds reported in this genus (as of June 2023).•Based on predicted drug-likeness, 81% of Zanthoxylum compounds obey Lipinski's rule of five.•Zanthoxylum compounds have comparable physicochemical properties to FDA-approved drugs.
Natural products (NPs) are essential in the search for new drugs to treat a wide range of diseases, including infectious and malignant disorders. However, despite the discovery of many bioactive NPs, they often do not make it to market as drugs due to toxicity and other challenges. The development of NPs into drugs is a long and expensive process, and many promising compounds are abandoned along the way. These molecules require in silico ADMET profiling in order to speed up their development into drugs lower costs, and the high attrition rate. The objective of this work was to produce thorough ADMET profiles of secondary metabolites from several classes that were isolated from Zanthoxylum species. The genus has a long history of therapeutic use, including treating tumours, hypertension, gonorrhea, coughs, bilharzia, chest pains, and toothaches. The study used a dataset of 406 compounds from the genus for theoretical ADMET analysis. The findings revealed that 81% of the compounds met Lipinski's rule of five, indicating good oral bioavailability. The drug-likeness criteria were taken into account, with percentages ranging from 66.2 to 88.1 percent. Additionally, 9.2% of the compounds were predicted to be lead-like, demonstrating their potential as promising drug development candidates. Interestingly, none of the compounds inhibited hERG I, while 33% inhibited hERG II, potentially having cardiac implications. Additionally, 30% of the compounds exhibited AMES toxicity inhibition, while 23.6% were identified as hepatotoxic and 22.2% would cause skin sensitivity. Moreover, 81.8% of the compounds demonstrated high intestinal absorption, making them desirable for oral drugs. In conclusion, these findings highlight the diverse properties of the investigated compounds and their potential for drug development.</abstract><cop>South Africa</cop><pub>Elsevier B.V</pub><pmid>37840557</pmid><doi>10.1016/j.sajb.2023.09.009</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-2074-1653</orcidid><orcidid>https://orcid.org/0000-0003-3890-7794</orcidid><orcidid>https://orcid.org/0000-0002-5171-1940</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0254-6299 |
ispartof | South African journal of botany, 2023-11, Vol.162, p.129-141 |
issn | 0254-6299 1727-9321 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10569136 |
source | Elsevier ScienceDirect Journals |
subjects | ADMET profiling Alkaloids bioavailability chest computer simulation data collection drug development Drug discovery Drug-likeness genus hepatotoxicity hypertension intestinal absorption Lead likeness Natural products phytochemicals Phytochemistry Secondary metabolites species therapeutics Zanthoxylum |
title | Therapeutic potential of the genus Zanthoxylum phytochemicals: A theoretical ADME/Tox analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T12%3A50%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20potential%20of%20the%20genus%20Zanthoxylum%20phytochemicals:%20A%20theoretical%20ADME/Tox%20analysis&rft.jtitle=South%20African%20journal%20of%20botany&rft.au=Wekesa,%20Emily%20N.&rft.date=2023-11-01&rft.volume=162&rft.spage=129&rft.epage=141&rft.pages=129-141&rft.issn=0254-6299&rft.eissn=1727-9321&rft_id=info:doi/10.1016/j.sajb.2023.09.009&rft_dat=%3Cproquest_pubme%3E2878017127%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2878017127&rft_id=info:pmid/37840557&rft_els_id=S0254629923005422&rfr_iscdi=true |